Hikma Targets $5B Revenue By 2030, Rebrands Generics Business To Hikma Rx

Hikma Pharmaceuticals hosted a group of sell-side analysts and investors at its advanced U.S. manufacturing and R&D site in Columbus, Ohio, where leadership from its Generics and Injectables divisions shared strategic plans for long-term growth. The event included tours of the 1,000,000 sq. ft. Columbus facility, which manufactures a range of oral, respiratory, and specialty generic medicines, as well as the company’s recently acquired injectables site in Bedford, Ohio.

As part of the event, Hikma unveiled medium-term financial guidance, targeting a 6–8% compound annual growth rate (CAGR) for group revenue and a 7–9% CAGR in core operating profit between 2024 and 2027. Additionally, Hikma announced an ambitious five-year revenue goal of $5 billion by 2030, signaling confidence in its U.S. operations and product portfolio.

Hikma decided to rebrand its Generics business as Hikma Rx to make it clearer that it now focuses on differentiated and complex prescription drugs. The rebrand suits Hikma’s goal to expand in branded generics and specialty segments, setting up the company for ongoing success in the evolving pharmaceutical industry.